Gordon, Dalia and Merrick, Dawn and Auld, Vanessa and Dunn, Robert and Goldin, Alan L. and Davidson, Norman and Catterall, William A. (1987) Tissue-specific expression of the RI and RII sodium channel subtypes. Proceedings of the National Academy of Sciences of the United States of America, 84 (23). pp. 8682-8686. ISSN 0027-8424 http://resolver.caltech.edu/CaltechAUTHORS:GORpnas87
See Usage Policy.
Use this Persistent URL to link to this item: http://resolver.caltech.edu/CaltechAUTHORS:GORpnas87
Anti-peptide antibodies that distinguish between the rat brain sodium channel subtypes referred to as RI and RII were prepared and used to determine their relative expression in nerve and muscle tissues. Sodium channels purified from rat brain are approximately 18% RI and 80% RII. In brain, the RII subtype is preferentially expressed with RI/RII ratios ranging from 0.07 in the hippocampus to 0.17 in the cerebral cortex. The RI subtype is preferentially expressed in more caudal areas of the central nervous system with values of RI/RII of 0.98 for medulla oblongata and 2.2 for spinal cord. Expression of additional unidentified sodium channel subtype(s) is detected in midbrain, medulla, and spinal cord, and expression of unidentified sodium channel subtypes predominates over expression of RI and RII in retina and optic nerve. The RI and RII subtypes are primarily expressed in the central nervous system and are not detected in significant numbers in skeletal or cardiac muscle, sympathetic ganglia, adrenal medulla, sciatic nerve, or cauda equina. The RII subtype appears first in development of both brain and spinal cord but declines in adult spinal cord as the RI subtype increases. The strict regional expression of these two sodium channel subtypes suggests that they may have distinct functional properties or physiological roles.
|Additional Information:||© 1987 by the National Academy of Sciences. Contributed by Norman Davidson, July 17, 1987. We thank Dr. Patrick Chou of the Howard Hughes Medical Institute Peptide Synthesis Facility and Drs. D. Blumenthal and E. Krebs of the Department of Pharmacology, University of Washington, for preparation of synthetic peptides. This work was supported by National Institutes of Health Research Grant NS15751 and U.S. Army Research Contract DAMD 17-84-C-4130 to W.A.C., National Institute of Health Research Grants to N.D., a grant from the Medical Research Council of Canada to R.D., a Dr. Chaim Weizmann Postdoctoral Research Fellowship to D.G., and a National Multiple Sclerosis Society Fellowship to A.L.G. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.|
|Usage Policy:||No commercial reproduction, distribution, display or performance rights in this work are provided.|
|Deposited By:||Tony Diaz|
|Deposited On:||13 Feb 2007|
|Last Modified:||26 Dec 2012 09:31|
Repository Staff Only: item control page